Weight Management

Ozempic

100% Online — No Office Visit Required

Ozempic is the brand name for semaglutide originally approved for type 2 diabetes — and has become widely used off-label for weight management due to its proven efficacy.

Brand name semaglutide (0.5–2mg)
Originally approved for type 2 diabetes
Widely used for weight management
Provider evaluation required

What Is Ozempic?

Ozempic is the Novo Nordisk brand formulation of semaglutide, available in 0.5mg and 1mg doses (with a 2mg option). It works identically to Wegovy (same molecule) but at different doses.

Who May Be a Candidate

Provider evaluation determines whether Ozempic or a related semaglutide formulation is appropriate for your situation.

How OakMD Works

OakMD is a telemedicine platform connecting eligible adults with licensed providers. If you're interested in Ozempic, the process begins with a brief online intake form. A licensed provider will review your health history, symptoms, and goals — and determine if treatment is appropriate for you.

If you are a candidate, your provider will create a personalized treatment plan and guide you through next steps. There are no in-person visits required.

Frequently Asked Questions

Common Questions

Is Ozempic approved for weight loss?

Ozempic is FDA-approved for type 2 diabetes management. Its use for weight loss is off-label. Wegovy, the higher-dose semaglutide, is specifically approved for chronic weight management.

Ready to Get Started?

Complete a brief online intake. A licensed provider will review your information and determine if treatment is appropriate for you.

Medical Disclaimer: The information on this page is provided for educational purposes only and does not constitute medical advice. OakMD is a telemedicine platform. All treatments are prescription-based, subject to provider review, and may not be appropriate for all individuals. A licensed provider will evaluate your medical history and determine eligibility. Consult a qualified healthcare professional before starting any new treatment.